GLP
GLP2-TZ
GIP/GLP-1 Dual Receptor Agonist — Tirzepatide
$89Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist based on the native GIP sequence with engineered GLP-1 receptor cross-reactivity. It features a C20 fatty diacid moiety enabling once-weekly pharmacokinetics in preclinical research applications.
Dual Incretin Agonism
Novel mechanism engaging both GIP and GLP-1 receptors, enabling study of synergistic incretin signaling pathways.
GIP-Based Scaffold
Built on the GIP peptide backbone with strategic amino acid modifications to confer GLP-1 receptor cross-reactivity.
C20 Fatty Acid Acylation
Extended fatty acid chain provides enhanced albumin binding for prolonged half-life in pharmacokinetic studies.
Tirzepatide: First approval as a dual GIP/GLP-1 receptor agonist
Review of tirzepatide's unique dual-agonist mechanism and preclinical research supporting its pharmacological profile.
| Product Name | GLP2-TZ (Tirzepatide) |
| CAS Number | 2023788-19-2 |
| Molecular Formula | C₂₂₅H₃₄₈N₄₈O₆₈ |
| Molecular Weight | 4813.45 Da |
| Purity | ≥99% (HPLC) |
| Physical Form | White Lyophilized Powder |
| Storage | -20°C, protected from light |
| Certification | Third-party HPLC & MS verified |
| Intended Use | Research and laboratory use only |
